From CNBC: 2024-05-02 14:34:45

Bausch Health Companies reported first-quarter top- and bottom-line misses with revenue of $2.15 billion, slightly below the $2.16 billion estimate. Adjusted EBITDA was $665 million, missing the consensus of $710 million. Investors are concerned about unresolved issues like Xifaxan litigation and Bausch + Lomb stake monetization, driving focus on key drugs like Xifaxan and future company milestones. Management reiterated fiscal 2024 guidance, expecting sales between $9.3 billion to $9.55 billion with adjusted EBITDA ranging from $3.2 billion to $3.35 billion. (Source: CNBC)



Read more at CNBC:: Bausch Health investors are left in a holding pattern, overhangs remain unresolved